Ketanserin降低清醒自发性高血压大鼠血压波动性的机理初探

应用计算机化清醒大鼠血流动力学测定技术，观察５－ＨＴ２受体阻滞剂Ｒｉｔａｎｓｅｒｉｎ（Ｒｉｔ）和α１受体阻滞剂哌唑嗪对清醒自发性高血压大鼠（ＳＨＲ）的血压、血压波动性（ＢＰＶ）和动脉压力感受性反射血压控制部分（ＡＢＲ－ＢＰ）的效应，旨在初步探讨兼具５－ＨＴ２受体和α１受体阻滞作用地新型抗高血压药Ｋｅｔａｎｓｅｒｉｎ降低ＢＰＶ的机制。结果表明：Ｒｉｔ对ＳＨＲ无降压作用，但侧脑室给药明显提高ＡＢＲ－Ｂ     

辐照氟银猪皮的实验研究

报道辐照氟银猪皮的制备、实验检测（弹性、创面粘附力和透水性测定，含银量测定）组织学检查细菌检测及抑菌试验研究，结果表明：辐照氟银猪皮除延伸度低于未辐照猪皮外，其撕裂强度、创面粘合力和透水性均与未辐照猪皮相似。组织学检查示：辐照氟银猪皮组织结构完整，表皮细胞部分空泡形成。组织细菌检测证明其无菌生长，达到无菌要求。抑菌试验证明对金黄色葡萄球菌、绿脓杆菌、大肠杆菌、变形杆菌、克雷伯氏菌均有极强的抑菌作用     

结核分枝杆菌Ag85B/GST融合蛋白表达载体构建及在大肠杆菌中的表达

目的 构建结核分枝杆菌Ag85B／GSF融合蛋白表达质粒，并在大肠杆菌(E．coli)中诱导表达。方法 以质粒pUC18／Ag85B为模板，用PCR法扩增结核杆菌Ag85B基因，扩增的Ag85B上游含有EcoR Ⅰ酶切位点，下游含有SalⅠ酶切位点；将Ag85B基因定向插入质粒pGEX-4T-1中，构建原核表达质粒pGEX-Ag85B并转化E．coli B121，筛选阳性重组子，限制性内切酶切鉴定和DNA序列测定，异丙基硫代半乳糖苷(IPTG)诱导表达，SDS-PAGE和Westem blot鉴定结果。结果 成功构建原核表达质粒pGEX-Ag85B并表达出Mr约56000大小的Ag85B／GSY融合蛋白，表达量占总菌体的30％。结论 为进一步进行纯化Ag85B蛋白和研究其在膀胱肿瘤治疗中的作用奠定了基础。     

雅施达协助心房颤动复律的临床观察

目的 观察雅施达改善胺碘酮对持续性心房颤动的转律效果.方法 持续性心房颤动病人78例,口服胺碘酮0.6 g/d,疗程2周.随机分为2组,即雅施达组和非雅施达组,观察转律成功率和转律成功所需时间.结果 雅施达组胺碘酮转律成功率70.5%(24/34),显著高于非雅施达组42.1%(16/38,P＜0.05);雅施达组转律平均时间为(9.1±0.35)d,显著少于非雅施达组(11.7±0.47)d(P＜0.01).结论 对持续性心房颤动病人进行胺碘酮转律治疗,加用雅施达可提高转律成功率,缩短转律所需时间.     

Hepatic pseudotumor in long-standing biliary atresia patients undergoing liver transplantation.

A pseudotumor, giant regenerative nodule, or macroregenerative nodule is an unusual benign hepatic lesion in biliary atresia (BA) patients. This tumor may mimic malignant transformation and may preclude liver transplantation (LT). The clinical and imaging surveillance of patients after the Kasai procedure is therefore an important aspect of management of BA patients. Our objective is to report our experience and describe the incidence, imaging, and pathologic features of pseudotumors in BA patients awaiting LT. From August 1990 to December 2006, 133 LTs for BA were performed. Five (3.8%; 4 female, 1 male) patients were diagnosed with pseudotumor. The patients' records were reviewed. The diagnostic imaging modalities used were abdominal ultrasound (US), computed tomography (CT) scan, and magnetic resonance imaging (MRI). Histologic confirmation of the lesions was obtained in all cases. All underwent the Kasai operation in early infancy. Six of 7 lesions in 4 of 5 patients were demonstrated by pretransplant imaging. Two of 7 tumors were detected by US. Five of 7 lesions were detected by CT, and 5 of 7 lesions were demonstrated by MRI. In 1 patient, the lesion was not seen in the US, CT, or MRI but was found during surgery and confirmed by histology. An additional tumor was found incidentally during histologic examination in a patient previously diagnosed to have 2 tumors by CT and MRI. In another patient diagnosed to have 2 tumors on imaging, pathology revealed only a single tumor. In conclusion, although unusual, pseudotumor should be included in the differential diagnosis of liver masses in BA children.     

骨形态发生蛋白复合明胶羟基磷灰石涂层多孔钛修复兔骨缺损的实验研究

目的 研究骨形态发生蛋白-2（BMP-2）复合明胶羟基磷灰石（HA）涂层多孔钛对兔股骨远端骨缺损的修复作用。方法 以多孔钛粉末为原料，制备三维多孔结构钛载体，然后运用碱热处理＋模拟体液等化学方法进行HA涂层，制备具有三维空间结构的HA涂层多孔钛复合材料。36只新西兰兔随机分为实验组及对照组，制备股骨远端圆柱状骨缺损模型，实验组植入复合BMP-2的HA涂层多孔钛材料，对照组单纯植入HA涂层多孔钛材料。分别于6、12、24周取材通过组织学和生物力学分析。结果组织学观察显示于各时间点实验组骨生成均不同程度优于对照组；生物力学测试显示在推出实验中所有样品的剪切应力都随时间增长而增大。其中在6周、12周实验组多孔钛在所有时间点均表现出了比对照组高得多的剪切力（P〈0．05），在24周实验组和对照组差异无统计学意义（P〉0．05）。结论 BMP-2复合明胶HA涂层多孔钛较单纯HA涂层多孔钛植入早期具有更良好的生物相容性、骨传导性及骨诱导性，可成功修复兔股骨远端骨缺损。     

体外循环浅低温心脏不停跳心内直视手术的临床研究

目的:探讨体外循环浅低温心脏不停跳心内直视手术的方法、疗效评价及其对心肌保护作用。方法:总结2004年3月～2008年12月间12例施行浅低温心脏不停跳心内直视手术病例,并行循环不阻断主动脉,鼻咽温维持在32～35℃,阻断上、下腔静脉,完成心内直视手术。结果:全组无围手术期死亡,心脏手术结束能顺利停机,术后血流动力学平稳,无严重心律失常,血尿发生率0%,无1例发生空气栓塞。1例心房切口缝合针眼渗血,行再次开胸止血,1例术后第32h发生急性肺梗塞,均经治疗痊愈。结论:浅低温心脏不停跳心内直视手术技术安全可行,是一种接近生理状态的心肌保护方法,可避免再灌注损伤,有较理想的心肌保护效果。     

拉萨地区冠心病与幽门螺杆菌感染相关性研究

目的探讨西藏拉萨地区幽门螺杆菌（Helicobacter pyloric，Hp）感染与冠心病及多种危险因素的关系。为该地区冠心病的防治提供依据。方法分为冠心病组46例和非冠心病组51例，应用检测血抗HpIgG及-C-尿素呼气试验方法检测Hp感染情况，并分别测定各组血脂、血糖、餐后2h血糖、C反应蛋白、纤维蛋白原、白细胞总数。结果冠心病组患者血清抗HpIgG阳性率为50．0％（23／46），明显高于非冠心病组的23．5％（12／51），P〈0．05；冠心病患者Hp现症感染率为54．3％（25／46），明显高于非冠心病组的31．3％（27／51），P〈0．05；冠心病组Hp感染患者血脂、空腹及餐后2h血糖、C反应蛋白、纤维蛋白原较非感染患者明显升高（P〈0．05）。结论Hp感染与冠心病相关，可能是拉萨地区冠心病发病的独立危险因素。     

Intraoperative blood loss is a risk factor for complications in donors after living donor hepatectomy.

Complications in a donor are a distressing but inevitable occurrence, since graft procurement is a major undertaking. Although the technique for procurement has some similarities to hepatic resection, a donor is very unlike a patient with malignancy. The risk factors identified in these patients cannot be extrapolated to donors. Donor hepatectomy carried out from June 1995 to March 2005 in Chang Gung Memorial Hospital, Kaohsiung Medical Center was reviewed with the aim of identifying risk factors for complications. There were 204 living donor liver transplants, with 205 donor hepatectomies, as 1 living donor liver transplantation was a dual graft. Ten donors (4.88%) suffered complications. There was no difference in terms of age, gender, body weight, operation, and parenchymal time between those who had complications and those who did not. There was also no difference in liver function tests between the 2 groups of donors, but the total bilirubin was significantly higher in donors with complications. The graft weight and remnant liver volume were also similar. The proportion of donors with fatty liver was the same between the 2 groups. The mean blood loss in donors with complications was 170 +/- 79 mL, and that for donors without complications was 95 +/- 77 mL. There was a statistically significant greater blood loss in donors with complications (P < 0.05). The number of segments removed in donors with complications was also higher compared to donors without complications (P < 0.03). Using multivariate analysis, intraoperative blood loss and the number of segments removed were found to be independent risk factors for donor complications. Intraoperative blood loss during graft procurement must be kept low to minimize complications in donors.